Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 4,129 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neck Neoplasms Clear all

Conditions: Advanced Cervical Adenocarcinoma, Advanced Vaginal Carcinoma, Advanced Vulvar Carcinoma, Human Papillomavirus-Related Cervical Squamous Cell Carcinoma, Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma, Metastatic Cervical Adenocarcinoma, Metastatic Cervical Carcinoma, Metastatic Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Metastatic Vaginal Adenocarcinoma, Metastatic Vaginal Carcinoma, Metastatic Vulvar Carcinoma, Recurrent Cervical Adenocarcinoma, Recurrent Cervical Carcinoma, Recurrent Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Stage III Cervical Cancer AJCC v8, Stage III Vaginal Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIA Vulvar Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IIIB Vulvar Cancer AJCC v8, Stage IIIC Vulvar Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Vaginal Cancer AJCC v8, Stage IVB Vulvar Cancer AJCC v8, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Vulvar Adenocarcinoma, Vulvar Squamous Cell Carcinoma
Interventions: Durvalumab, Laboratory Biomarker Analysis, Stereotactic Radiosurgery, Tremelimumab; Biological · Other · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Dallas, Texas • Houston, Texas

Conditions: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions: Computed Tomography, Fludeoxyglucose F-18, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Positron Emission Tomography, Sodium Fluoride F-18; Procedure · Other · Radiation + 1 more
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Esophageal Cancer
Interventions: Liquid nitrogen spray cryotherapy with the truFreeze device; Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Subject
Interventions: Broccoli Sprout Extract (BSE); Drug
Lead sponsor: Julie E. Bauman, MD, MPH; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Appendix Carcinoma, Colon Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Malignant Digestive System Neoplasm, Pancreatic Carcinoma, Rectal Carcinoma, Small Intestinal Carcinoma, Anal Carcinoma, Digestive System Carcinoma, Digestive System Neuroendocrine Tumor, Pancreatic Neuroendocrine Tumor
Interventions: Acupuncture Therapy, Acupressure Therapy, Oral Cryotherapy, Questionnaire Administration, Quality-of-Life Assessment; Procedure · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer, Colorectal Cancer, Pancreas Cancer, Appendix Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Esophagus Cancer, Urothelial Carcinoma, Sarcoma
Interventions: CBX-12; Drug
Lead sponsor: Cybrexa Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 4
States / cities: New Haven, Connecticut • Austin, Texas • Houston, Texas + 1 more

Conditions: Oral Leukoplakia
Interventions: 5-fluorouracil; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cervical Cancer
Interventions: recombinant interferon alpha-2b, isotretinoin, paclitaxel; Biological · Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 6
States / cities: Hamilton, New Jersey • Morristown, New Jersey • New Brunswick, New Jersey + 2 more

Conditions: Head and Neck Cancers
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 1,468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV, Cervical Cancer Stigma
Interventions: Neutral Video, Storytelling, Self disclosure, Combination, Video, Waitlist; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Dysphagia, Pain, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma
Interventions: Dexamethasone, Placebo, Quality-of-Life Assessment, Questionnaire Administration, Transoral Robotic Surgery; Drug · Other · Procedure
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
Interventions: Bapotulimab (BAY1905254), Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 8
States / cities: Tucson, Arizona • New Haven, Connecticut • Chicago, Illinois + 5 more

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: OncoPrism-HNSCC™; Diagnostic Test
Lead sponsor: Cofactor Genomics, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cervical Cancer, Hpv, Warts
Interventions: Quadrivalent HPV for types 6, 11, 16 and 18; Biological
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 9 Years to 17 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Cancer of the Cervix, Cancer of the Endometrium
Interventions: Novel nano-scintillator fiber-optic dosimeter (nanoFOD); Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Cervical Carcinoma
Interventions: AL3818, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Carboplatin; Drug
Lead sponsor: Advenchen Laboratories, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 8
States / cities: Long Beach, California • Miami, Florida • Lexington, Kentucky + 5 more

Conditions: Head and Neck Cancer, Patients Requiring a Free Flap Surgery
Interventions: FloTrac; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Esophageal Cancer
Interventions: paclitaxel; Drug
Lead sponsor: Theradex; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 30
States / cities: Mobile, Alabama • Loma Linda, California • San Francisco, California + 25 more

Conditions: Nicotine Dependence, Other Tobacco Product, Bladder Cancer, Lung Cancer, Cancer of Head and Neck
Interventions: HALO; Device
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Avelumab, Palbociclib, Cetuximab; Drug
Lead sponsor: Kathryn Gold; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Thyroid Cancer
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Human Papilloma Virus (HPV), Cervical Cancers
Interventions: Self-sampling with urine, Self-sampling with swab, In-clinic Pap/HPV co-testing; Device
Lead sponsor: University of Texas at Austin; Other
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 735 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Carcinoma of Unknown Primary, Head and Neck Cancer
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Head and Neck Cancer, Mucositis Oral, Radiation Toxicity, Tongue Cancer
Interventions: sargramostim, oral salt and soda mouthwash; Biological · Other
Lead sponsor: Marilyn Dodd; Other
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers

PET/CT Assessment of Radiation-Induced Vascular Complications in Head and Neck Cancer

Spray Cryotherapy for Esophageal Cancer (ICE-CANCER)

Broccoli Sprout Extracts in Healthy Volunteers: A Pilot Study of Nrf2 Pathway Modulation in Oral Mucosa

Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer

Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Intralesional 5-fluorouracil Injection for the Treatment of Oral Leukoplakia

Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or Persistent Cervical Cancer

Collection Of Tissue, Blood, and Other Specimens From Patients With Head and Neck Tumors To Study the Causes, Diagnosis, Prevention and Treatment of Cancers

RISE: Reducing Cancer and HIV Stigma Through Empowerment

Dexamethasone in Reducing Oral Pain and Dry Mouth After Surgery in Patients With Oropharyngeal Cancer

Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.

Predicting Immunotherapy Efficacy in Head and Neck Squamous Cell Cancer

Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?

Real Time In-Vivo Dosimetry For Gynecologic Brachytherapy

Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

A Prospective Study Evaluating the Use of Intraoperative Stroke Volume Variation Via the FloTrac Device to Guide Fluid and Vasopressor Management in Head and Neck Free Flaps

Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus

Evaluation of Appeal and Impact of E-Cigarettes Among Chronic Smokers With Smoking-Related Cancers

Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

CASE 1320: RAI Uptake and Serum Prolactin in Thyroid Cancer

Unidos Contra el VPH

PET Scans and CT Scans in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy

GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer